GM-CSF clinical trials: pediatric aplastic anemia and Fanconi's anemia.
Two clinical trials were undertaken to evaluate the effect of human recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) in pancytopenic pediatric patients with aplastic anemia and Fanconi's anemia. In the aplastic anemia trial, 9 out of 12 patients had some improvement when treated with GM-CSF. In the Fanconi's anemia trial, 6 of 7 patients showed some improvement when treated with GM-CSF. For both groups, improvement in white blood cell count and absolute neutrophil count were the most common response. Side effects observed during these studies were fever, rash, urticaria, and flu-like symptoms. Nursing care of both groups focused on the effects of pancytopenia, as well as the potential adverse effects of GM-CSF. Patient education focused on teaching drug preparation and storage, subcutaneous injection, and potential side effects.
Lopez
K D
KD
Guinan
E C
EC
D000293:Adolescent; D000741:Anemia, Aplastic / Q000097:blood / Q000451:nursing / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D005199:Fanconi Anemia / Q000097:blood / Q000451:nursing / Q000628:therapy*; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male
D016178:Granulocyte-Macrophage Colony-Stimulating Factor